KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Non-Current Assets (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Other Non-Current Assets data on record, last reported at $1.8 billion in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 60.32% year-over-year to $1.8 billion; the TTM value through Dec 2025 reached $1.8 billion, up 60.32%, while the annual FY2025 figure was $1.8 billion, 60.32% up from the prior year.
  • Other Non-Current Assets reached $1.8 billion in Q4 2025 per REGN's latest filing, up from $1.7 billion in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.8 billion in Q4 2025 and bottomed at $142.9 million in Q2 2021.
  • Average Other Non-Current Assets over 5 years is $699.3 million, with a median of $409.9 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: dropped 18.58% in 2021, then skyrocketed 196.28% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $145.9 million in 2021, then skyrocketed by 130.57% to $336.4 million in 2022, then soared by 32.02% to $444.1 million in 2023, then soared by 155.8% to $1.1 billion in 2024, then surged by 60.32% to $1.8 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $1.8 billion in Q4 2025, $1.7 billion in Q3 2025, and $1.5 billion in Q2 2025.